SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-18-024570
Filing Date
2018-10-22
Accepted
2018-10-22 08:00:19
Documents
5
Period of Report
2018-10-21
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agle-8k_20181022.htm 8-K 34442
2 EX-99.1 agle-ex991_105.htm EX-99.1 15503
3 EX-99.2 agle-ex992_7.htm EX-99.2 1184
4 GRAPHIC g0kwip1iiwo3000001.jpg GRAPHIC 130387
5 GRAPHIC gkjsyb2sco2t000001.jpg GRAPHIC 3061
  Complete submission text file 0001564590-18-024570.txt   236376
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 181131547
SIC: 2834 Pharmaceutical Preparations